Coronary CT Angiogram: What Your Numbers Change About Your Treatment

What a Coronary CT Angiogram Actually Measures

A CCTA is not a single-number blood test. It is a contrast-enhanced CT scan that builds a three-dimensional map of your coronary arteries and produces multiple clinically actionable outputs: a coronary artery calcium score, a stenosis grade for each vessel, a plaque composition profile, and (in many centers) a CT-derived fractional flow reserve.

The calcium score, reported as an Agatston score, quantifies calcified plaque in the coronary arteries. It ranges from 0 (no detectable calcium) to well above 1 to 000 in patients with heavy plaque burden. The Multi-Ethnic Study of Atherosclerosis (MESA) established percentile-based interpretation by age, sex, and ethnicity, showing that even modest calcium (CAC 1 to 99) carries roughly double the cardiovascular event risk compared to a score of zero over 10 years 1. Stenosis grading classifies each artery segment as minimal (below 25%), mild (25 to 49%), moderate (50 to 69%), or severe (70% or above). The 2021 AHA/ACC Chest Pain Guideline assigns CCTA a Class I (Level of Evidence A) recommendation for evaluating stable chest pain in patients at low-to-intermediate pretest probability 2.

Plaque composition matters too. Non-calcified ("soft") plaque, identified by lower Hounsfield unit density on CT, is associated with higher rupture risk. A 2019 analysis from the CONFIRM registry (N=2,042) found that patients with predominantly non-calcified plaque had a 5-year major adverse cardiac event rate 2.7 times higher than those with purely calcified plaque at similar stenosis levels 3.

How a CAC Score of Zero Changes Your Prescription

A calcium score of zero is a powerful risk reclassifier. For patients whose 10-year atherosclerotic cardiovascular disease (ASCVD) risk falls in the borderline (5 to 7.5%) or intermediate (7.5 to 20%) range, a CAC of zero may justify deferring statin therapy.

The 2018 AHA/ACC Cholesterol Guideline explicitly states that a CAC score of zero is a "risk-enhancing" factor (or in this case, a risk-lowering reclassifier) that can guide the shared decision-making conversation about statins 4. This matters because roughly 50% of adults aged 40 to 75 with intermediate ASCVD risk have a CAC of zero, according to MESA data 1. These patients have a 10-year event rate below 5%, which places them below the threshold where statin benefit clearly outweighs risk. The exception is important: patients with diabetes, familial hypercholesterolemia, or LDL above 190 mg/dL should receive statins regardless of their calcium score, per the same guideline 4.

A zero score does not mean zero risk forever. Repeat imaging at 5 to 10 years may be reasonable for patients who remain in a borderline risk category 5.

CAC 1 to 99: The Threshold for Starting Statins

Even mild coronary calcium changes prescribing. A score of 1 to 99 confirms subclinical atherosclerosis and, in most intermediate-risk patients, tips the decision toward statin initiation.

The MESA cohort showed that adults with CAC 1 to 99 had a 10-year coronary heart disease event rate of approximately 7.5%, compared to 1.5% in those with CAC zero 1. That absolute risk increase makes moderate-intensity statin therapy (atorvastatin 10 to 20 mg or rosuvastatin 5 to 10 mg) the typical first move. Some clinicians also add ezetimibe if baseline LDL is above 130 mg/dL, though guideline language at this calcium level stops short of mandating combination therapy 4.

Beyond pharmacotherapy, a CAC of 1 to 99 also changes behavioral counseling intensity. The 2019 ACC/AHA Primary Prevention Guideline recommends using the calcium score to reinforce lifestyle modification adherence in patients who might otherwise underestimate their risk 5. Seeing plaque on a scan motivates patients. A randomized trial by Kalia et al. found that patients who received CAC score feedback had significantly better LDL reduction at 4 years compared to controls who received standard counseling alone 6.

CAC 100 to 399: High-Intensity Statin Territory

A calcium score between 100 and 399 places a patient at meaningfully elevated cardiovascular risk regardless of their calculated 10-year ASCVD score. Treatment intensity increases.

High-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) becomes the default recommendation at this level 4. Low-dose aspirin (75 to 100 mg daily) enters the conversation for patients without elevated bleeding risk, though the 2019 ACC/AHA Primary Prevention Guideline limits its strongest recommendation to patients aged 40 to 70 with higher ASCVD risk 5. Blood pressure targets may also tighten. The SPRINT trial demonstrated that a systolic blood pressure target below 120 mmHg reduced cardiovascular events by 25% in high-risk adults (N=9,361), and a CAC of 100 or above is one marker that may justify applying that more aggressive target 7.

Referral patterns shift here too. Many primary care physicians will involve a cardiologist when the CAC exceeds 100, particularly if the patient has symptoms or additional risk factors like diabetes or a strong family history of premature coronary disease.

CAC 400 and Above: Aggressive Multi-Drug Therapy

A calcium score at or above 400 places the patient in the highest risk tier. Five-year event rates in this group approach 20% in some cohorts.

This is where treatment escalation becomes most aggressive. Maximally tolerated high-intensity statin therapy is the foundation. If LDL remains above 70 mg/dL (the typical target for established atherosclerotic disease or high-risk primary prevention), adding ezetimibe is the next step. For patients who still do not reach goal, PCSK9 inhibitors (evolocumab or alirocumab) enter the algorithm. The FOURIER trial (N=27,564) showed that evolocumab added to statin therapy reduced the composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15% over a median of 2.2 years 8. A CAC above 400, especially combined with CAC above the 75th percentile for age, sex, and race, is considered equivalent to a "coronary artery disease equivalent" for risk stratification purposes 4. Dr. Michael Blaha, Director of Clinical Research at the Johns Hopkins Ciccarone Center, has noted: "A CAC score over 400 effectively places a patient into the same risk category as someone with known coronary disease, and our treatment intensity should reflect that reality." The full medication profile at this level often includes high-intensity statin, ezetimibe if needed, aspirin (after bleeding risk assessment), an ACE inhibitor or ARB for blood pressure, and potentially a PCSK9 inhibitor for persistent LDL elevation.

How Stenosis Grade Changes the Intervention Decision

While the calcium score guides pharmacotherapy intensity, the stenosis grade determines whether intervention beyond medication becomes necessary. The distinction between anatomical narrowing and functional significance is the critical pivot point.

Stenosis below 50% is treated medically. Optimal medical therapy (statin, aspirin, blood pressure control, glucose management, and smoking cessation) remains the standard for non-obstructive coronary artery disease. The ISCHEMIA trial (N=5,179) confirmed that among patients with stable coronary disease and moderate or severe ischemia, an initial invasive strategy did not reduce the risk of death or MI compared to optimal medical therapy over a median of 3.2 years 9.

Stenosis at 50% or above requires functional assessment. CT-FFR, which estimates the pressure drop across a stenosis using computational fluid dynamics applied to the CT images, helps determine whether a lesion is flow-limiting. A CT-FFR at or below 0.80 suggests hemodynamic significance. The PLATFORM trial demonstrated that a CT-FFR-guided strategy reduced the rate of finding no obstructive disease at invasive angiography from 73% to 12%, dramatically cutting unnecessary catheterizations 10. Patients with CT-FFR above 0.80 can often be managed medically even with anatomically moderate stenosis. Those at or below 0.80 are referred for invasive coronary angiography, where the interventionalist decides between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) based on lesion complexity, vessel involvement, and patient factors.

Plaque Composition: Why the Type Matters as Much as the Amount

Two patients can have identical calcium scores and stenosis percentages but face different risks based on what their plaque is made of. CCTA's ability to characterize plaque composition adds a layer of risk stratification that traditional stress testing cannot provide.

Calcified plaque (high Hounsfield unit density) is generally considered more stable. Non-calcified or "soft" plaque (low attenuation plaque, or LAP) has features associated with vulnerability to rupture: a thin fibrous cap, a large lipid core, and positive remodeling of the vessel wall. A 2020 study in the Journal of the American College of Cardiology (N=1,769) found that the presence of high-risk plaque features on CCTA predicted a 5-year hazard ratio of 5.2 for acute coronary syndrome events, independent of stenosis severity 11.

The treatment implication is direct. Patients with high-risk plaque features may benefit from more aggressive LDL lowering. The GLAGOV trial demonstrated that evolocumab plus statin therapy produced plaque regression (measured by intravascular ultrasound) when LDL was reduced to a median of 36.6 mg/dL, compared to continued progression with statin alone (LDL 93 mg/dL) 12. Some clinicians now use the presence of non-calcified plaque on CCTA as justification for targeting LDL well below 70 mg/dL, even in primary prevention patients who lack other traditional indications for that threshold. Anti-inflammatory therapy is another consideration. The CANTOS trial showed that canakinumab (an interleukin-1β inhibitor) reduced recurrent cardiovascular events in patients with elevated high-sensitivity C-reactive protein 13. While canakinumab is not widely prescribed due to cost and infection risk, colchicine (0.5 mg daily) has emerged as a more practical anti-inflammatory option after the LoDoCo2 trial (N=5,522) showed a 31% relative risk reduction in cardiovascular events 14.

How CCTA-Guided Care Reduces Heart Attacks: The SCOT-HEART Evidence

The strongest evidence that CCTA results meaningfully change outcomes, not just prescriptions, comes from the SCOT-HEART trial.

SCOT-HEART randomized 4,146 patients with stable chest pain to standard care plus CCTA versus standard care alone. At 5 years, the CCTA group had a 41% lower rate of coronary heart disease death or nonfatal myocardial infarction (2.3% vs. 3.9%, P=0.004) 15. The mechanism was not more stents or bypasses. It was better preventive therapy. Patients in the CCTA arm were more likely to receive appropriate statin and antiplatelet therapy after their scan results.

Dr. David Newby, the lead investigator, stated: "CCTA doesn't just find disease. It motivates both clinicians and patients to act on what they find, and that action is what reduces events." The trial's results helped drive the Class I recommendation for CCTA in the 2021 AHA/ACC Chest Pain Guideline 2 and the 2016 NICE update (CG95) that made CCTA the first-line investigation for stable chest pain in the United Kingdom 16.

Who Should Not Get a Coronary CT Angiogram

CCTA is not appropriate for everyone, and understanding contraindications is part of using the results responsibly.

Patients with an irregular heart rhythm (particularly uncontrolled atrial fibrillation) produce motion artifacts that degrade image quality. Severe renal impairment (eGFR below 30 mL/min/1.73 m²) is a relative contraindication because of iodinated contrast dye 17. A known allergy to iodinated contrast requires premedication or an alternative test. Pregnancy is an absolute contraindication due to radiation exposure. The effective radiation dose of a modern CCTA is approximately 1 to 5 mSv with prospective ECG gating, comparable to 1 to 2 years of background radiation 2.

CCTA is also not the right test for acutely symptomatic patients with ST-elevation on ECG. Those patients need emergent invasive angiography. Ordering a CT scan in that scenario delays life-saving reperfusion therapy.

From Scan to Prescription: A Practical Decision Map

Translating CCTA output into a medication plan follows a structured algorithm that integrates calcium score, stenosis, plaque type, and functional data.

For a patient with CAC zero and no stenosis: lifestyle modification, no statin (if borderline or intermediate ASCVD risk without diabetes or familial hypercholesterolemia), and reassessment in 5 to 10 years. For CAC 1 to 99 with non-obstructive plaque: moderate-intensity statin, aggressive lifestyle counseling, and repeat risk assessment in 3 to 5 years. For CAC 100 to 399: high-intensity statin, aspirin after bleeding risk evaluation, blood pressure optimization per SPRINT targets, and cardiology referral if symptomatic. For CAC 400 or above: maximum-tolerated statin, ezetimibe, PCSK9 inhibitor consideration, aspirin, and cardiology co-management.

If stenosis reaches 50% or above, CT-FFR determines the next step. A value above 0.80 supports continued medical therapy with close follow-up. A value at or below 0.80 triggers referral for invasive coronary angiography, where the interventional cardiologist and cardiac surgeon determine the optimal revascularization strategy based on the SYNTAX score and patient-specific factors 9.

Colchicine 0.5 mg daily may be considered for patients with confirmed atherosclerotic disease and elevated inflammatory markers, based on LoDoCo2 evidence 14.